Purine enzyme profile in human colon-carcinoma cell lines and differential sensitivity to deoxycoformycin and 2'-deoxyadenosine in combination. 1995

M Camici, and M Turriani, and M G Tozzi, and G Turchi, and J Cos, and C Alemany, and A Miralles, and V Noe, and C J Ciudad
Dipartimento di Fisiologia e Biochimica, UniversitĂ  di Pisa, Italy.

Different cell lines, 2 from human colon carcinoma (LoVo and HT29) and 1 from Chinese hamster ovary (CHO K-I), were examined to assess the effect of deoxycoformycin (dCF), an inhibitor of adenosine deaminase (ADA), and 2'-deoxyadenosine (dAdo) on their growth. When used alone, neither dCF or dAdo were cytotoxic for the 3 cell lines, while their combination caused inhibition of cell growth, with the following sensitivity: CHO K-I > LoVo > HT29. We studied the pattern of enzymatic activities involved in the metabolism of dAdo in the 3 cell lines. The phosphorylation of dAdo by adenosine kinase appears to play a central role in the toxicity of the deoxynucleoside in combination with dCF. In fact, CHO K-I cells, which are the most sensitive, possess the highest level of this enzyme. Moreover, the cytotoxic effect was almost completely reversed in the 3 cell lines when inhibitors of adenosine kinase, such as 5'-amino-5'-deoxyadenosine and iodotubercidine, were added to the culture medium together with dCF and dAdo. In addition, baby hamster kidney (BHK) adenosine-kinase-deficient (AK-) cells were highly resistant to this treatment. Uptake inhibition of dAdo using dipyridamole also caused reversal of the toxicity. The AMP and deoxyAMP dephosphorylating activities, much lower in the CHO K-I cells, also appear to play a central role in the toxicity of dAdo when adenosine deaminase is inhibited. However, our data suggest that other factors may modulate the toxic effect, such as S-adenosyl-homocysteine-hydrolase inhibition by dAdo at high concentrations.

UI MeSH Term Description Entries
D011687 Purines A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D003839 Deoxyadenosines Adenosine molecules which can be substituted in any position, but are lacking one hydroxyl group in the ribose part of the molecule. Adenine Deoxyribonucleosides,Adenylyldeoxyribonucleosides,Deoxyadenosine Derivatives,Deoxyribonucleosides, Adenine,Derivatives, Deoxyadenosine
D004176 Dipyridamole A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Antistenocardin,Apo-Dipyridamole,Cerebrovase,Cléridium,Curantil,Curantyl,Dipyramidole,Kurantil,Miosen,Novo-Dipiradol,Persantin,Persantine,Apo Dipyridamole,Novo Dipiradol
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000248 Adenosine Kinase An enzyme that catalyzes the formation of ADP plus AMP from adenosine plus ATP. It can serve as a salvage mechanism for returning adenosine to nucleic acids. EC 2.7.1.20. Kinase, Adenosine
D000964 Antimetabolites, Antineoplastic Antimetabolites that are useful in cancer chemotherapy. Antineoplastic Antimetabolites
D012435 S-Adenosylhomocysteine 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions. S Adenosylhomocysteine,Adenosylhomocysteine, S

Related Publications

M Camici, and M Turriani, and M G Tozzi, and G Turchi, and J Cos, and C Alemany, and A Miralles, and V Noe, and C J Ciudad
March 1998, International journal of cancer,
M Camici, and M Turriani, and M G Tozzi, and G Turchi, and J Cos, and C Alemany, and A Miralles, and V Noe, and C J Ciudad
October 2000, Journal of cellular biochemistry,
M Camici, and M Turriani, and M G Tozzi, and G Turchi, and J Cos, and C Alemany, and A Miralles, and V Noe, and C J Ciudad
December 1985, The Tohoku journal of experimental medicine,
M Camici, and M Turriani, and M G Tozzi, and G Turchi, and J Cos, and C Alemany, and A Miralles, and V Noe, and C J Ciudad
November 1978, Journal of immunology (Baltimore, Md. : 1950),
M Camici, and M Turriani, and M G Tozzi, and G Turchi, and J Cos, and C Alemany, and A Miralles, and V Noe, and C J Ciudad
November 1982, Blood,
M Camici, and M Turriani, and M G Tozzi, and G Turchi, and J Cos, and C Alemany, and A Miralles, and V Noe, and C J Ciudad
April 1995, British journal of cancer,
M Camici, and M Turriani, and M G Tozzi, and G Turchi, and J Cos, and C Alemany, and A Miralles, and V Noe, and C J Ciudad
September 1997, Biochemical and biophysical research communications,
M Camici, and M Turriani, and M G Tozzi, and G Turchi, and J Cos, and C Alemany, and A Miralles, and V Noe, and C J Ciudad
January 2003, Journal of biochemical and molecular toxicology,
M Camici, and M Turriani, and M G Tozzi, and G Turchi, and J Cos, and C Alemany, and A Miralles, and V Noe, and C J Ciudad
April 1981, Biochemical pharmacology,
M Camici, and M Turriani, and M G Tozzi, and G Turchi, and J Cos, and C Alemany, and A Miralles, and V Noe, and C J Ciudad
February 1992, Thymus,
Copied contents to your clipboard!